DelveInsight’s ‘Hypertension Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline hypertension therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hypertension pipeline domain.

 

Key Takeaways from the Hypertension Pipeline Report

• DelveInsight’s hypertension pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for hypertension treatment. 
• Key hypertension companies such as Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics,  and others are evaluating novel hypertension drugs candidate to improve the treatment landscape.
• Promising hypertension pipeline therapies in various stages of development include Firibastat, Baxdrostat (CIN-107), MLS-101, Zilebesiran (ALN-AGT), Ifetroban, IONIS-AGT-LRx, QLS-101, ID140009, KBP-5074, AER-90, ION904, TPN171H, FM101, AJU-C52L, T4030, L606, AV-101 , CKD-351, ABI-009, WB007, DE-130A, OTX-TIC, PRM-125, LivaloVA, NCX 470, RT234, PA5346, PHP-201, LTP001, CS1, TRC150094, JV-GL1, BI 685509, MK-5475, AGN-193408, Sotatercept, HCP1803, GB002, SPH3127, Treprostinil Palmitil, GMA301, rodatristat ethyl, BAY1237592, PRO-122,  VVN-539, Ralinepag, Tacrolimus, PB6440, MGX292,  KER-012, and others.
• In the second quarter of 2022, PhaseBio completed the development and optimization of a robust manufacturing process to support anticipated upcoming proof-of-concept trials, positioning the program for initial GMP manufacturing runs in the fourth quarter of 2022. PB6440 is a highly selective aldosterone synthase inhibitor in development to target treatment resistant hypertension and other indications where elevated aldosterone is known to contribute to disease process, such as uncontrolled hypertension, chronic kidney disease, and heart failure.
• In July 2022, Invex Therapeutics received approval to commence the Phase III IIH EVOLVE clinical trial of Presendin to treat idiopathic intracranial hypertension (IIH) patients in Australia. The approvals include those from Human Research Ethics Committee (HREC) and the clearance for Clinical Trial Notification (CTN) scheme by the Australian Therapeutic Goods Administration (TGA). Developed by Peptron, Presendin is a sustained release (SR) Exenatide microsphere formulation intended to be administered subcutaneously once a week.
• In June 2022, Attgeno AB announced that it received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a Phase II clinical trial of its lead drug candidate Supernitro as a potentially lifesaving treatment for patients with acute pulmonary hypertension after cardiac surgery.
• In June 2022, Gossamer Bio, Inc. announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary hemodynamics, reduction in NT-proBNP, reverse remodeling of pulmonary vascular pathology, and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.
• In May 2022, Idorsia Ltd announced positive top-line results of PRECISION, the Phase III study investigating aprocitentan, Idorsia’s dual endothelin receptor antagonist, for the treatment of patients whose blood pressure is not adequately controlled despite receiving at least triple antihypertensive therapy – known as resistant hypertension. Aprocitentan significantly reduced blood pressure when added to standardized combination background antihypertensive therapy in patients with resistant hypertension over 48 weeks of treatment.
• In May 2022, United Therapeutics received the US Food and Drug Administration approval for its therapeutic Tyvaso DPI. Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United determined that inhalation of Tyvaso DPI is one of the easiest ways for patients to administer a prostacyclin or the treatment for PAH.
• In February 2022, Ferrer strengthened its focus on pulmonary vascular and interstitial lung diseases, as well as neurological disorders, by signing of a distribution agreement with United Therapeutics Corporation for Tyvaso (treprostinil) inhalation solution – a pharmaceutical drug-device combination product for the treatment of WHO Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD).

 

Request a sample and discover the recent advances in hypertension treatment drugs @ Hypertension Pipeline Report

 

The hypertension pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage hypertension products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the hypertension pipeline landscape.

 

Hypertension Overview

High blood pressure (hypertension) is a common condition in which the blood’s long-term force against your artery walls is high enough to cause health problems such as heart disease. Age, smoking, drinking, overweight are among the prominent factors for causes of hypertension. 

Even when blood pressure readings reach dangerously high levels, most people with high blood pressure have no hypertension symptoms. Some people with high blood pressure may experience headaches, shortness of breath, or nosebleeds. Still, these signs and hypertension symptoms aren’t specific and usually don’t appear until the high blood pressure has progressed to a severe or life-threatening level.

Several tests such as ECG, EKG, Echocardiogram, Ambulatory monitoring, la tests, and others are used for hypertension diagnosis.

 

Find out more about hypertension medications @ Hypertension Treatment Drugs

 

A snapshot of the Hypertension Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Firibastat	Quantum Genomics	Phase III	Glutamyl aminopeptidase inhibitors	Oral
SPH3127	Shanghai Pharmaceuticals Holding Co., Ltd	Phase III	Renin inhibitors	Oral
STN1012600	Santen Pharmaceutical	Phase III	Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists	Ophthalmic
NCX 470	Nicox	Phase III	Nitric oxide donors	Ophthalmic
ION904	Ionis Pharmaceuticals	Phase II	RNA interference	Subcutaneous
Baxdrostat	CinCor Pharma	Phase II	Aldosterone synthase inhibitors	Oral
MLS-101	Mineralys Therapeutics	Phase II	Aldosterone synthase inhibitors	Oral
IONIS-AGT-LRx	Ionis Pharmaceuticals	Phase II	Angiotensinogen inhibitors; RNA interference	Subcutaneous
GB002	Gossamer Bio	Phase II	Platelet-derived growth factor receptor antagonists	Inhalation
AGN-193408	AbbVie	Phase I/II	NA	Opthalmic
FM101	Future Medicine	Phase I/II	Adenosine A3 receptor antagonists	Oral
GMA-301	Gmax Biopharm	Phase I	Endothelin A receptor antagonists	Intravenous
AER-901	Aerami Therapeutics	Phase I	Bcr-abl tyrosine kinase inhibitors	Inhalation
ID140009	IlDong Pharmaceutical Co Ltd	Phase I	Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors	NA
PB 6440	PhaseBio Pharmaceuticals	Preclinical	Aldosterone synthase inhibitors	Oral
MGX292	Centessa Pharmaceuticals	Preclinical	Growth differentiation factor 2 replacements	NA

 

Learn more about the emerging hypertension pipeline therapies @ Hypertension Clinical Trials

 

Hypertension Therapeutics Assessment

The hypertension pipeline report proffers an integral view of the hypertension emerging novel therapies segmented by stage, product type,  molecule type,  mechanism of action, and route of administration.

 

Scope of the Hypertension Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
• Therapeutics Assessment By Mechanism of Action: Glutamyl aminopeptidase inhibitors, Aldosterone synthase inhibitors, Angiotensinogen expression inhibitors, RNA interference, Angiotensin type 1 receptor antagonists, Calcium channel antagonists, Cholesterol absorption inhibitors, HMG-CoA reductase inhibitors, NPC1L1 protein inhibitors, Nitric oxide donors; Rho-associated kinase inhibitors, Growth differentiation factor 2 replacements
• Key Hypertension Companies: Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, and others
• Key Hypertension Pipeline Therapies: Firibastat, Baxdrostat (CIN-107), MLS-101, Zilebesiran (ALN-AGT), Ifetroban, IONIS-AGT-LRx, QLS-101, ID140009, KBP-5074, AER-90, ION904, TPN171H, FM101, AJU-C52L, T4030, L606, AV-101 , CKD-351, ABI-009, WB007, DE-130A, OTX-TIC, PRM-125, LivaloVA, NCX 470, RT234, PA5346, PHP-201, LTP001, CS1, TRC150094, JV-GL1, BI 685509, MK-5475, AGN-193408, Sotatercept, HCP1803, GB002, SPH3127, Treprostinil Palmitil, GMA301, rodatristat ethyl, BAY1237592, PRO-122,  VVN-539, Ralinepag, Tacrolimus, PB6440, MGX292,  KER-012, and others.

 

Dive deep into rich insights for drugs for hypertension treatment, visit @ Hypertension Treatment 

Table of Contents

1.	Hypertension Pipeline Report Introduction
2.	Hypertension Pipeline Report Executive Summary
3.	Hypertension Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Hypertension Pipeline Therapeutics
6.	Hypertension Pipeline: Late Stage Products (Pre-registration)
7.	Hypertension Pipeline: Late Stage Products (Phase III)
7.1	Firibastat: Quantum Genomics
8.	Hypertension Pipeline: Mid Stage Products (Phase II)
8.1	ION904: Ionis Pharmaceuticals
9.	Hypertension Pipeline: Early Stage Products (Phase I)
9.1	AER-901: Aerami Therapeutics
10.	Hypertension Pipeline Therapeutics Assessment
11.	Inactive Products in the Hypertension Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Hypertension Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services